Navigation Links
DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
Date:4/10/2013

®), unless either or both are contra-indicated.

Pharmacokinetic data reported by the Company demonstrated a dose response as expected based on observations reported in the historical literature.  In addition, the Company previously presented data supporting the activity of VAL-083 against GBM tumors expressing resistance to the current front-line therapy, Temodar.

Mr. Bacha continued, "While these data are preliminary in nature, we have seen an overall response rate of 33.3%, where tumor growth had stabilized or regressed, in patients that had failed other therapies. We believe these data along with the differentiated mechanism of action of VAL-083, which supports potential activity when other therapies face tumor resistance, provides strong rationale for the further development of VAL-083."

Mr. Bacha further noted that doses of VAL-083 within the Company's proposed target doses had achieved reported response rates as high as 40 percent in historical GBM clinical trials sponsored by the U.S. National Cancer Institute (NCI).

"We look forward to continuing to work with our clinical investigators toward determining an optimal dosing regimen for future registration trials and to the potential opportunity of offering patients a valuable new treatment option for these aggressive brain cancers," added Mr. Bacha.

The company's permanent AACR abstract (#4672) can be viewed by clicking here or searching the following link http://www.abstractsonline.com/Plan/AdvancedSearch.aspx

About VAL-083VAL-083 represents a 'first-in-class' small-molecule chemotherapeutic. VAL-083 has been assessed in multiple NCI-sponsored clinical s
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
2. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
3. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
4. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
5. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
6. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
7. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
8. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
9. Global Pharmacy Automation Market 2012-2016 with McKesson Corp., ScriptPro LLC, Parata Systems LLC Dominating
10. Global Pharmaceutical Leader Chooses Acsis Enterprise Serialization Management Suite to Achieve e-Pedigree Compliance
11. Zosano Pharma, Inc. Announces Key Strategic Hire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 XRpro ... for drug discovery and development services which features ... the pharmaceutical industry, announced financial results for the ... Timothy C.  Tyson, Chairman of XRpro Sciences commented, ... successfully transition from development stage to commercial stage ...
(Date:3/27/2015)... March 27, 2015 According to ... (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, RF, ... Indication (AF, VT, WPW) - Global Forecasts to 2019 ", ... to reach around ~$4.73 Billion by 2019 with a ... to 2019. Browse   90   ...
(Date:3/27/2015)... Mass. , March 27, 2015 /PRNewswire/ ... and privately-held MirImmune LLC, today announced that ... agreement to RXi,s novel and proprietary sd-rxRNA® ... cancer immunotherapies. The collaboration has the potential ... patient friendly cancer treatments that could be ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5
... SUNNYVALE, California, September 23, 2010, ... ... ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Reata Pharmaceuticals Announce Agreement to Develop and... -- ABBOTT PARK, Ill. and IRVING, Texas, Sept. 23 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
Cached Medicine Technology:Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 2Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 3Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 4Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 5Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 6Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 7Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 8Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 9Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 10Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 2Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 3Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 4Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 5Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 6Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 7Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 8Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 9
(Date:3/28/2015)... India Network visitor health insurance ... to all visitors who purchase the plan before arrival ... encouraged to purchase the insurance program as soon as ... coverage for pre-existing medical conditions. Parents and grandparents traveling ... conditions with serious consequences to their health. Many visitors ...
(Date:3/28/2015)... IL (PRWEB) March 28, 2015 Centurion Service ... equipment auction on Thursday, April 2 at their Las Vegas ... Vegas, NV 89081. The sale, which consists of equipment from ... begin promptly at 9 a.m. PDT. , Buyers will ... and surgery equipment. “We are a one-stop-shop,” said Erik Tivin, ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... surgery experiences re-injury, according to research presented today at ... ) Specialty Day. The study examined the long term ... younger. , “We examined survey data from 242 ... noted lead author Justin P. Roe, MBBS, FRACS, from ...
(Date:3/28/2015)... Delaying rotator cuff surgery on patients ... research presented today at the American Orthopaedic Society for ... study compared results for 170 patients who received rotator ... joint capsule release procedure to relieve stiffness at the ... author from St. George Hospital in Sydney, Australia. “Both ...
(Date:3/28/2015)... Genomic medicine experts have sequenced the genomes of ... time, key information for understanding and treating this intractable ... story on the Surviving Mesothelioma website. , ... British Columbia Cancer Agency, and PhenoPath lab in Seattle, ... and mutations that can lead to peritoneal mesothelioma ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2
... DQE offers a ... , ... The DQE Training Division is offering a new program to help hospitals better prepare for ... advanced level Hospital Incident Command System (HICS) training held at the client’s hospital. ...
... , ... ... ... ...
... ... ... , , ... ...
... ... ... , , ... ...
... ... ... , , , ... ...
... ... ... ... ...
Cached Medicine News:Health News:DQE Offers New Hospital Command Center Training 2Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 2Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 3Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 4Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 5Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 6Health News:Statewide Poll: Pennsylvania Must Adequately Fund Senior Care Services 2Health News:Statewide Poll: Pennsylvania Must Adequately Fund Senior Care Services 3Health News:Rep. Fattah Endorses Obama Health Care Bill, Refuses to Disarm in Procedural Dispute 2Health News:Craneware Reports Six Monthly Financial Results 2Health News:Craneware Reports Six Monthly Financial Results 3Health News:Craneware Reports Six Monthly Financial Results 4Health News:International Merchant Advisors CEO Mel Roseman to Discuss New Medical Marijuana Clinics Live on CBS Radio Network's Big Biz Show February 22, 2010 at 1:40 pm PST 2Health News:International Merchant Advisors CEO Mel Roseman to Discuss New Medical Marijuana Clinics Live on CBS Radio Network's Big Biz Show February 22, 2010 at 1:40 pm PST 3Health News:International Merchant Advisors CEO Mel Roseman to Discuss New Medical Marijuana Clinics Live on CBS Radio Network's Big Biz Show February 22, 2010 at 1:40 pm PST 4
Straight shafts with 2.0 mm, 1 x 2 Elschnig style teeth. Serrated handle with polished finish. Handle: Wide....
Curved shafts with micro Pierse type tips. Flat open serrated handle with dull finish....
Colibri style 0.1 mm Pierse tips. Flat smooth handle with dull finish....
Curved shafts with 0.5 mm, 1 x 2 teeth. Serrated handle with thumb catch lock and polished finish....
Medicine Products: